Provisional experiences with the combination of L-dopa and L-deprenyl

  • G. Ulm
  • F. Fornadi
Conference paper
Part of the Key Topics in Brain Research book series (KEYTOPICS)


In a retrospective study three different groups of patients are compared: patients on L-dopa on its own, patients on L-dopa plus L-deprenyl and patients on L-dopa plus Ergot-derivatives. The aim of the study was to find out if there was any advantage gained from one of these strategies. The study showed that the combination-therapy was superior to L-dopa alone; it did not matter whether L-dopa was combined with L-deprenyl or with an Ergot-derivative.


Federal Republic Motor Movement Toxic Radical Nigrostriatal Dopaminergic Neuron Provisional Experience 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson’s disease: a long term study. J Neural Transm 644: 113–127CrossRefGoogle Scholar
  2. Csanda E, Antal J, Fornadi F (1980) Clinical experience in extrapyramidal diseases with selective MAO-B-inhibitor, L-deprenyl. In: Magyar K (ed) Monoamine exidase and their selective inhibitors. Akadémiai Kiadó, Budapest/Pergamon Press, Oxford, pp 127–132Google Scholar
  3. Glover V, Gibb C, Sandler M (1986) Monoamine oxidase B (MAO-B) is the major catalyst of 1-methy1–4-phenyl-1, 2, 3, 6-tetrahydropyridine ( MPTP) oxidation in human brain and other tissues. Neurosci Lett 64: 216–220PubMedCrossRefGoogle Scholar
  4. Knoll J (1987) R-(-)-deprenyl (selegeline, movergan®) facilitates the activity of the nigrostriatal dopaminergic neuron. J Neural Transm [Suppl] 25: 45–66Google Scholar
  5. Lees AJ (1987) Surrent controversies in the use of selegiline hydrochloride. J Neural Transm [Suppl] 25: 157–162Google Scholar
  6. Marsden CD, Sandler M (1986) The MPTP story: an introduction. J Neural Transm [Suppl] 20: 1–3Google Scholar
  7. Sandler M, Willoughby J, Glover V, Gibb C (1987) Selegiline and the prophylaxis of Parkinson’s disease. J Neural Transm [Suppl] 25: 35–43Google Scholar
  8. Tetrud JW, Langston JW (1987) R-(-)-deprenyl as a possible protective agent in Parkinson’s disease. J Neural Transm [Suppl] 25: 69–79Google Scholar
  9. Ulm G, Fornadi F (1987) R-(-)-deprenyl in the treatment of end-of-dose akinesia. J Neural Transm [Suppl] 25: 163–172Google Scholar

Copyright information

© Springer-Verlag/Wien 1989

Authors and Affiliations

  • G. Ulm
    • 1
  • F. Fornadi
    • 2
  1. 1.Paracelsus-Elena-KlinikKasselFederal Republic of Germany
  2. 2.Parcelsus-NordseeklinikHelgolandFederal Republic of Germany

Personalised recommendations